Vera Therapeutics (VERA) Stock Price, News & Analysis

Company Overview

VERA Therapeutics, Inc. (NASDAQ: VERA) is a clinical-stage biopharmaceutical company based in San Diego, California. The company is focused on the discovery, development and commercialization of innovative therapies for immune-mediated and gastrointestinal diseases. By integrating translational science with targeted drug design, VERA aims to deliver first-in-class or best-in-class treatments that address significant unmet medical needs.

VERA’s lead program is an oral, gut-selective small molecule designed to inhibit tissue transglutaminase-2 for the treatment of celiac disease. In parallel, the company is advancing a novel therapeutic candidate that modulates key inflammatory pathways in patients with inflammatory bowel disease (IBD). Both programs have demonstrated encouraging preclinical results and are currently progressing through early-stage clinical trials, with initial data anticipated to guide later-stage development.

Founded in 2016, VERA Therapeutics has rapidly built a diversified pipeline through a combination of in-house research and strategic collaborations. The company completed an initial public offering in 2021 and has established partnerships to support global clinical development and potential commercialization efforts. With operations and trial sites in North America and Europe, VERA is positioned to engage with regulatory authorities and clinical networks across key markets.

VERA’s leadership team brings together experienced executives from leading pharmaceutical and biotechnology firms, combining expertise in immunology, clinical development and commercial strategy. The board of directors includes recognized authorities in gastroenterology, translational medicine and drug development, providing a strong governance framework to advance VERA’s mission of bringing safe and effective therapies to patients worldwide.

Key Stats

• Today's Range: $23.71 to $24.36
• 50-Day Range: $18.87 to $32.00
• 52-Week Range: $18.53 to $51.61
• Volume: 554,123 shs
• Average Volume: 996,597 shs
• Market Capitalization: $1.52 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $65.00
• Consensus Rating: Buy

Vera Therapeutics Stock Analysis - MarketRank™

Vera Therapeutics scored higher than 83% of companies evaluated by MarketBeat, and ranked 186th out of 944 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.6 / 5
• Analyst Rating: Buy

Consensus Rating

Vera Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.10, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Vera Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Vera Therapeutics are expected to decrease in the coming year, from ($2.89) to ($3.13) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vera Therapeutics is -7.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vera Therapeutics is -7.94, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Vera Therapeutics has a P/B Ratio of 2.62. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.23% of the float of Vera Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Vera Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vera Therapeutics has recently decreased by 98.33%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vera Therapeutics does not currently pay a dividend.

Dividend Growth

Vera Therapeutics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

0.23% of the float of Vera Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Vera Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vera Therapeutics has recently decreased by 98.33%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.1 / 5
• News Sentiment: 0.75

News Sentiment

Vera Therapeutics has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.99 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for Vera Therapeutics this week, compared to 6 articles on an average week.

Search Interest

Only 4 people have searched for VERA on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

13 people have added Vera Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 8% compared to the previous 30 days.

Company Ownership

• Score: 4.2 / 5
• Insider Trading: Acquiring Shares

Insider Buying vs. Insider Selling

In the past three months, Vera Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,277,598.00 in company stock and sold $0.00 in company stock.

Percentage Held by Insiders

16.30% of the stock of Vera Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

99.21% of the stock of Vera Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

VERA Stock Analysis - Frequently Asked Questions

How have VERA shares performed this year?

Vera Therapeutics' stock was trading at $42.29 on January 1st, 2025. Since then, VERA stock has decreased by 43.7% and is now trading at $23.82.

How were Vera Therapeutics' earnings last quarter?

Vera Therapeutics, Inc. (NASDAQ:VERA) posted its quarterly earnings data on Thursday, May, 8th. The company reported ($0.81) earnings per share for the quarter, missing analysts' consensus estimates of ($0.75) by $0.06.

When did Vera Therapeutics IPO?

Vera Therapeutics (VERA) raised $66 million in an initial public offering (IPO) on Friday, May 14th 2021. The company issued 4,400,000 shares at a price of $14.00-$16.00 per share. Jefferies, Cowen and Evercore ISI served as the underwriters for the IPO.

How do I buy shares of Vera Therapeutics?

Shares of VERA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Vera Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Vera Therapeutics investors own include CRISPR Therapeutics (CRSP), Pure Storage (PSTG), NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Adobe (ADBE) and Arista Networks (ANET).

Company Calendar

• Last Earnings: 5/08/2025
• Today: 7/12/2025
• Next Earnings (Estimated): 8/06/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VERA
• CIK: 1831828
• Web: veratx.com
• Phone: 650-770-0077
• Fax: N/A
• Employees: 40
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Vera Therapeutics: $65.00
• High Price Target: $100.00
• Low Price Target: $26.00
• Potential Upside/Downside: +172.9%
• Consensus Rating: Buy
• Rating Score (0-4): 3.10
• Research Coverage: 10 Analysts

Profitability

• EPS (Trailing Twelve Months): ($3.00)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$152.15 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -40.59%
• Return on Assets: -34.54%

Debt

• Debt-to-Equity Ratio: 0.10
• Current Ratio: 27.68
• Quick Ratio: 27.68

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $9.08 per share
• Price / Book: 2.62

Miscellaneous

• Outstanding Shares: 63,770,000
• Free Float: 53,379,000
• Market Cap: $1.52 billion
• Optionable: Optionable
• Beta: 1.19